Sarcopenia is an independent prognostic factor in elderly patients with diffuse large B-cell lymphoma treated with immunochemotherapy
| Autor: | Hervé Tilly, Hélène Lanic, Romain Modzelewski, Florian Clatot, Jean Michel Picquenot, Sylvain Mareschal, Jerôme Kraut-Tauzia, Fabrice Jardin, Aspasia Stamatoullas, Stéphane Leprêtre |
|---|---|
| Přispěvatelé: | Service d'Hématologie, Centre de Lutte Contre le Cancer Henri Becquerel Normandie Rouen (CLCC Henri Becquerel), Equipe Quantification en Imagerie Fonctionnelle (QuantIF-LITIS), Laboratoire d'Informatique, de Traitement de l'Information et des Systèmes (LITIS), Institut national des sciences appliquées Rouen Normandie (INSA Rouen Normandie), Institut National des Sciences Appliquées (INSA)-Normandie Université (NU)-Institut National des Sciences Appliquées (INSA)-Normandie Université (NU)-Université de Rouen Normandie (UNIROUEN), Normandie Université (NU)-Université Le Havre Normandie (ULH), Normandie Université (NU)-Institut national des sciences appliquées Rouen Normandie (INSA Rouen Normandie), Normandie Université (NU), Groupe d'étude des proliférations lymphoïdes (GPL), Université de Rouen Normandie (UNIROUEN), Normandie Université (NU)-Normandie Université (NU)-Institut National de la Santé et de la Recherche Médicale (INSERM), Breton, Céline, Service d'Oncologie Médicale, CRLCC Haute Normandie-Centre de Lutte Contre le Cancer Henri Becquerel Normandie Rouen (CLCC Henri Becquerel), service d'anatomo-pathologie, CRLCC Henri Becquerel, Equipe Quantification en Imagerie Fonctionnelle ( QuantIF-LITIS ), Laboratoire d'Informatique, de Traitement de l'Information et des Systèmes ( LITIS ), Université Le Havre Normandie ( ULH ), Normandie Université ( NU ) -Normandie Université ( NU ) -Université de Rouen Normandie ( UNIROUEN ), Normandie Université ( NU ) -Institut national des sciences appliquées Rouen Normandie ( INSA Rouen Normandie ), Normandie Université ( NU ) -Université Le Havre Normandie ( ULH ), Normandie Université ( NU ), Groupe d'étude des proliférations lymphoïdes ( GPL ), Université de Rouen Normandie ( UNIROUEN ), Normandie Université ( NU ) -Normandie Université ( NU ) -Institut National de la Santé et de la Recherche Médicale ( INSERM ), CRLCC Haute Normandie-CRLCC Henri Becquerel |
| Rok vydání: | 2013 |
| Předmět: |
Male
Sarcopenia MESH : Retrospective Studies MESH : Antineoplastic Combined Chemotherapy Protocols Body Surface Area MESH : Aged Gastroenterology Body Mass Index 0302 clinical medicine Antineoplastic Combined Chemotherapy Protocols MESH : Muscle Skeletal MESH: Sarcopenia ComputingMilieux_MISCELLANEOUS MESH: Treatment Outcome Aged 80 and over 0303 health sciences education.field_of_study Prognosis 3. Good health [SDV] Life Sciences [q-bio] MESH: Antineoplastic Combined Chemotherapy Protocols Oncology Vincristine 030220 oncology & carcinogenesis Rituximab MESH : Vincristine medicine.medical_specialty Tomography Scanners X-Ray Computed MESH : Tomography Scanners X-Ray Computed MESH: Prognosis MESH: Body Mass Index MESH: Doxorubicin 03 medical and health sciences Humans MESH : Aged 80 and over education Cyclophosphamide Aged Retrospective Studies MESH: Age Factors MESH: Humans [ SDV ] Life Sciences [q-bio] MESH : Humans MESH : Prednisone MESH: Cyclophosphamide MESH: Retrospective Studies MESH : Organ Size medicine.disease MESH : Body Mass Index MESH : Sarcopenia MESH: Antibodies Monoclonal Murine-Derived MESH: Prednisone MESH: Female Body mass index Diffuse large B-cell lymphoma Cancer Research MESH: Organ Size [SDV]Life Sciences [q-bio] MESH : Lymphoma Large B-Cell Diffuse Antibodies Monoclonal Murine-Derived MESH: Aged 80 and over MESH: Body Surface Area International Prognostic Index Prednisone hemic and lymphatic diseases MESH : Female MESH : Cyclophosphamide MESH: Aged Body surface area MESH: Muscle Skeletal MESH : Prognosis Age Factors Hematology Organ Size Treatment Outcome Female Lymphoma Large B-Cell Diffuse medicine.drug MESH : Body Surface Area MESH : Male Population MESH: Vincristine MESH : Treatment Outcome Internal medicine medicine MESH : Doxorubicin Muscle Skeletal 030304 developmental biology MESH: Tomography Scanners X-Ray Computed business.industry MESH: Male MESH : Antibodies Monoclonal Murine-Derived Surgery Doxorubicin MESH: Lymphoma Large B-Cell Diffuse MESH : Age Factors business |
| Zdroj: | Leukemia & lymphoma Leukemia & lymphoma, Taylor & Francis, 2014, 55 (4), pp.817-23 Leukemia and Lymphoma American Society of Hemathology annual meeting American Society of Hemathology annual meeting, Dec 2011, San Diego, United States. ahead of American Society of Hemathology annual meeting, Dec 2011, San Diego, United States. ahead of print, 2013 |
| ISSN: | 1029-2403 1042-8194 |
| Popis: | International audience; Approximately 25-35% of patients with diffuse large B-cell lymphoma (DLBCL) are older than 70 years. The aim of this study was to investigate the prognostic impact of depletion of skeletal muscle (sarcopenia) in elderly patients with DLBCL. This retrospective analysis included 82 patients with DLBCL older than 70 years and treated with R-CHOP (rituximab, cyclophosphamide, doxorubicin, Oncovin, prednisone) or R-miniCHOP. Sarcopenia was measured by the analysis of stored computed tomography (CT) images at the L3 level at baseline. The surface of the muscular tissues was selected according to the CT Hounsfield unit. This value was normalized for stature in order to calculate the lumbar L3 skeletal muscle index (LSMI, in cm(2)/m(2)). The mean age of the population was 78 years. According to the defined cut-offs for LSMI, 45 patients with DLBCL were considered sarcopenic. Sarcopenic patients displayed a higher revised International Prognostic Index (R-IPI) compared with patients without sarcopenia, and were older, with a mean age of 80 years and 77 years, respectively (p = 0.006). With a median follow-up of 39 months, the 2-year overall survival in the sarcopenic population was 46% compared with 84% in the non-sarcopenic group (HR = 3.22; 95% CI = 1.73-5.98; p = 0.0002). In a multivariate analysis, sarcopenia remained predictive of outcome (p = 0.005). Sarcopenia is a relevant and predictive factor in elderly patients with DLBCL treated with rituximab plus chemotherapy. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|